SecBot SecBot

BNTC

Benitec Biopharma Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001808898 Biotech & Drug Discovery
$8.59 −0.06 (−0.69%)
Oct 26 4:00 PM ET · prev $8.65
Market cap
$307.7M
Small cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$24.00
+179% · range $14.00–32.00
Next earnings
Nov 12
in 17 days · EPS est. −$0.29
1 year
−45.3%
from $15.70 · Oct 27
30 days
−14.3%
from $10.02
52-week range
$8.11–16.36
−47% from high · low Oct 16
Avg volume 20D
187.1K
Oct 5 spike 584.2K
Short interest
2.04M
≈5.8% of shares · −6.7%
Days to cover
10.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 6 reports · 90 days
Balance 1 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Benitec Biopharma filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 13 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.280 → −$0.288 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest −6.7% to 2.04M shares. 10.2 days to cover, ≈5.8% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCADD921,299$12.3M
Schonfeld Strategic Advisors LLCADD235,357$3.1M
VANGUARD PORTFOLIO MANAGEMENT LLCADD143,510$1.9M
CITADEL ADVISORS LLCTRIM81,466$1.1M
Bank of New York Mellon CorpADD60,061$803.6K
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.DOUBLED45,106$603.5K
Nuveen, LLCTRIM28,339$379.2K
RHUMBLINE ADVISERSADD26,242$351.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +179%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 23, 2026Raymond James
INITIATE
INITIATEOutperform
Sep 15, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Jul 28, 2026Wedbush
INITIATE
INITIATEOutperform
May 12, 2026Evercore ISI Group
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 29, 2026
BUCHI J KEVIN
Director
GIFT51,813 sh
May 26, 2026
Friedman David Matthew
Director
AWARD35,000 sh

Earnings setup

Estimates
Nov 12
reports in 17 days
−$0.29
EPS estimate, this quarter
−3%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.29-$0.34–-$0.26-3.0%$0.00
Next Q-$0.30-$0.34–-$0.26-1.1%$0.00
Current FY-$1.22-$1.47–-$1.06-4.5%$0.00
Next FY-$1.43-$1.64–-$1.20-7.9%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
BNTC Q1 2027 Earnings Scheduled — 2026-11-12
Recent
Sep 21, 2026
Earnings date
BNTC Q4 2026 Earnings After Market Close — 2026-09-21
Sep 14, 2026
Earnings
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
May 14, 2026
Earnings
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Q3 Earnings Release
May 12, 2026
Earnings date
BNTC Q3 2026 Earnings Scheduled — 2026-05-12
Mar 10, 2026
FDA
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene…

Short side

FINRA· Sep 30, 2026
2,039,457
shares short
-6.7%
vs prior settlement
10.2
days to cover
≈5.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Benitec Biopharma filed a DEFA14A notice of internet availability of proxy materials for its December 3, 2026 annual…
DEFA14A — Impact 2/10
Oct 20, 2026 SEC
Benitec Biopharma filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on…
DEF 14A — Impact 4/10
Oct 5, 2026 SEC
Benitec announced receipt of formal FDA feedback from a Type C meeting regarding the BB-301 pivotal study design. The…
8-K — Impact 4/10
Sep 21, 2026 Earnings calendar
BNTC Q4 2026 Earnings After Market Close — 2026-09-21
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
921,299 shares ($12.3M)
Jun 30, 2026 Inst.
Schonfeld Strategic Advisors LLC — ADD
235,357 shares ($3.1M)
Jun 29, 2026 Insider
BUCHI J KEVIN gifted 51,813 shares
Director
May 26, 2026 Insider
Friedman David Matthew was granted 35,000 shares
Director

SecBot reports

10 filings · 1 press release · 1 bullish · 1 bearish · 8 neutral
All BNTC filing & press-release reports (11)